A Study of Pirtobrutinib (LY3527727) in Participants With Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma

Description

This study will evaluate the long-term safety of pirtobrutinib in participants with previously treated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL). The study is open to those who completed J2N-MC-JZNN/LOXO-BTK-20020 (NCT 04666038) for continued access to the study intervention or continued follow-up visits. Treatment will be given every 4 weeks and this study is expected to last about 5 years.

Interventions

• Pirtobrutinib (Drug)
  Administered orally
• Idelalisib (Drug)
  Administered orally

Eligibility criteria

Conditions

Locations

• Mitchell Cancer Institute — Mobile, Alabama, United States
• Arizona Oncology Associates, P.C. - HOPE — Tucson, Arizona, United States
• Cancer Specialists, LLC — Jacksonville, Florida, United States
• Minnesota Oncology Hematology, P.A. — Coon Rapids, Minnesota, United States
• Cayuga Cancer Center — Ithaca, New York, United States
• Memorial Sloan-Kettering Cancer Center (MSKCC) - New York — New York, New York, United States
• Oncology Hematology Care Inc — Cincinnati, Ohio, United States
• Texas Oncology - Paris — Fort Worth, Texas, United States
• US Oncology - Texas Oncology — Kyle, Texas, United States
• The Alfred Hospital — Melbourne, Australia
• LKH - Universitätsklinikum der PMU Salzburg — Salzburg, Austria
• AZ Delta — Roeselare, Belgium
• Princess Margaret Cancer Centre - University Health Network — Toronto, Canada
• Xuanwu Hospital Capital Medical University — Beijing, China
• Hunan Cancer Hospital — Changsha, China
• Sun Yat-sen University Cancer Center — Guangdong, China
• Nanfang Hospital of Southern Medical University — Guangzhou, China
• Gansu Provincial Cancer Hospital — Lanzhou, China
• The First Affiliated Hospital of Nanchang University — Nanchang, China
• Fudan University Shanghai Cancer Center — Shanghai, China
• Taizhou Hospital of Zhejiang Province — Taizhou, China
• Hematology Hospital of the Chinese Academy of Medical Sciences — Tianjin, China
• Tianjin Medical University Cancer Institute & Hospital — Tianjin, China
• Affiliated Cancer Hospital of Xinjiang Medical University — Ürümqi, China
• The Affiliated Hospital of Xuzhou Medical College — Xuzhou, China
• Henan Cancer Hospital — Zhengzhou, China
• University Hospital Center Zagreb — Zagreb, Croatia
• Fakultni nemocnice Hradec Kralove — Hradec Králové, Czechia
• Centre Henri Becquerel — Rouen, France
• Del-pesti Centrumkorhaz - Orszagos Hematologiai es Infektologiai Intezet — Budapest, Hungary
• Debreceni Egyetem — Debrecen, Hungary
• St. James's Hospital — Dublin, Ireland
• Beaumont Hospital — Dublin, Ireland
• Tel Aviv Sourasky Medical Center — Tel Aviv, Israel
• Azienda Ospedaliero - Universitaria Nazionale Santi Antonio e Biagio e Cesare Arrigo — Alessandria, Italy
• Azienda Ospedaliera Universitaria Careggi — Florence, Italy
• Presidio Ospedaliero Papardo — Messina, Italy
• Fondazione IRCCS San Gerardo dei Tintori — Monza, Italy
• Azienda Ospedaliera di Perugia Ospedale S. Maria della Misericordia — Perugia, Italy
• Fondazione Policlinico Universitario Agostino Gemelli IRCCS — Rome, Italy
• Azienda Ospedaliera S. Maria Di Terni — Terni, Italy
• Tokai University Hospital — Isehara, Japan
• Szpital Specjalistyczny w Brzozowie Podkarpacki Ośrodek Onkologiczny im.ks.B.Markiewicza — Brzozów, Poland
• Szpital Uniwersytecki Nr 2 im. dr J. Biziela w Bydgoszczy — Bydgoszcz, Poland
• Pratia Onkologia Katowice — Katowice, Poland
• Hospital Universitario Marques De Valdecilla — Santander, Spain
• Hospital Universitario Virgen Del Rocio — Seville, Spain
• Castle Hill Hospital — Hull, United Kingdom
• St James's University Hospital — Leeds, United Kingdom
• GenesisCare — Newmarket, United Kingdom